Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 22;20(1):90–100. doi: 10.5217/ir.2020.00133

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Copyright 2022. Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1. — Comparison of thiopurine dosage, time to adverse events (AEs), cumulative continuation rate according to NUDT15 genotypes. (A) Maintenance dosage of 6-mercaptopurine (6-MP) and serum 6-thioguanine nucleotides (6-TGN) levels in patients with C/C and C/T genotypes. (B) Dosage of 6-MP at the time when total AEs was developed are plotted. (C) Time to total AEs after starting thiopurine treatment is plotted in term of NUDT15 genotypes. (D) Cumulative continuation rate of thiopurine for 120 months in patients with C/C and C/T genotypes. Azathioprine doses were converted to a 6-MP dose using a conversion factor of 2.08. Data represents median (interquartile range). ^aP < 0.05. RBCs, red blood cells.